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Summary 
 
Myostatin is an important negative regulator of muscle 
growth.  Natural mutations and knockouts in animals 
produce a “double-muscled” phenotype the basis of 
which is a dramatic increase in muscle mass.  
Therapeutics that target myostatin are currently in 
development.  There are almost no documented side 
effects of suppression, and early research suggests that 
myostatin inhibition can restore function in cases of 
muscular dystrophy.  Clinical trials are currently 
underway, although myostatin research has not taken 
advantage of some techniques like RNA interference.  
With the development of myostatin therapies and 
advances in gene therapy, the social and ethical 
implications of using these as performance 
enhancement strategies raise interesting questions 
about athleticism in general. 
 
History of Discovery 
 
For some time now, scientists have been characterizing the 
process by which muscle cells are formed by differentiation 
of myoblasts and subsequent fusion into long fibers with 
contractile properties.  It is clear that muscle growth in 
humans and other animals is not unlimited; thus, there must 
be a biochemical signal for myoblasts to stop differentiation 
and proliferation.  McPherron, Lawler, and Lee (1997) first 
identified the protein they called growth/differentiation factor-
8 (GDF-8) using PCR with primers designed from conserved 
regions of the transforming growth factor-B (TGF-B) 
superfamily.  The same group discovered that knockout of 
the myostatin gene in mice results in a doubling to tripling in 
the size of the mouse muscles.   
Soon after, Grobet et al. (1997) identified an 
eleven base pair deletion in the myostatin gene in the 
Belgian Blue cattle breed (BBCB) expressing the well-known 
double-muscled phenotype for that species.  The double-
muscled BBCB was the first observed phenotype resulting 
from a natural myostatin mutation, and it had been known 
and intentionally bred into cattle populations for some time 
before the molecular basis and inheritance patterns were 
truly understood.  More recently, the first documented case 
of myostatin in humans was published by Schuelke et al. 
(2004).  This case describes a 4-year-old German boy who 
was extraordinarily muscular from birth.  In the 11 years 
since its discovery, myostatin has become an intense area of 
focus because of its potential for alleviating muscle wasting, 
which is a common side effect of many diseases and 
treatments. 
 
Characterization of the Myostatin Gene and Expression 
 
Gonzalez-Cadavid et al. (1998) first characterized the 
human myostatin gene by scanning the human EST data 
bank for orthologs to the well-known mouse myostatin gene.  
They found that the coding region is approximately 6.2kbp 
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long with a small intron (1.8kbp) and a larger intron (2.4kbp) 
separating three exons.  This sequence resides on the 
2q33.2 chromosomal region and is transcribed into a 3.1kbp 
mRNA, which is then translated into a 375 amino acid 
myostatin protein precursor of size 26-kDa.  The precursor 
then undergoes further processing to form the mature 
myostatin protein of size 12-kDa.  This mature form of the 
protein dimerizes to form the active myostatin ligand.  
Human serum and skeletal muscle were demonstrated to 
contain only mature myostatin by Western blotting, but other 
human organs that are composed of smooth muscle tissue 
such as the colon, intestine, stomach, bladder, and prostate 
did not show any myostatin precursor or mature protein.  It 
was demonstrated by Sharma et al. (1999) that myostatin is 
expressed in both fetal and adult hearts and may play a role 
in the pathology of heart muscle.  In mice models myostatin 
is also expressed in skeletal muscle tissue and is 
measurable in serum; to a lesser extent in heart muscle in 
both developing and adult animals (McPherron et al., 1997).  
As will become obvious, the role of myostatin in tissues 
outside of skeletal muscle is poorly understood, but this is 
changing with the development of drugs that target 
myostatin. 
 
Biochemical Pathways of Myostatin Action 
 
Because myostatin clearly impacts the formation of muscle, 
it is necessary to have a basic picture of the process of 
muscle formation.  Muscle fiber formation begins with 
multipotent cells descendent from the mesoderm.  In the 
presence of the transcription factors MyoD or Myf5, which 
bind to DNA sites that activate muscle-specific genes, these 
cells commit to becoming mature muscle cells called 
myoblasts.  Myoblasts proliferate until they leave the cell 
cycle.  Then, multiple myoblasts line up together and fuse to 
form multinucleated myotubes.  These myotubes express 
proteins that allow them to become the contractile units we 
know as skeletal muscle tissue (Gilbert, 2000). 
With regard to the proliferation of myoblasts, 
Joulia et al. (2003) demonstrated, using flow cytometry that 
myostatin overexpression leads to an accumulation of 
myoblasts in the G0/G1 and G2 phases and thus are not 
available for differentiation into myotubes.  They also 
inhibited myostatin by expressing a myostatin mRNA 
antisense gene and found that cells were influenced in the 
opposite way: to withdraw from the cell cycle and begin 
differentiation.  Patterns of expression of several other genes 
were measured, and it was determined that myostatin exerts 
its effects by moderating myogenin and increasing the 
expression of p21 and p53, both of which are involved in 
cell-cycle control. 
 
 
 
Figure 1. A normal whippet on the left and a whippet exhibiting the 
double-muscled phenotype on the right. 
(http://www.dailymail.co.uk/pages/live/articles/news/news.html?in_arti
cle_id=467985&in_page_id=1770). 
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A step past proliferation of myoblasts on the way 
to muscle fibers is their differentiation, which appears to be 
affected by myostatin as well.  Joulia et al. (2003) also found 
that the production of myotubes, which are the 
multinucleated fused form of maturing myoblasts, was 
inhibited in myostatin-overexpressing cells.  Similarly, 
Langley et al. (2002) showed that adding myostatin to 
growth medium with bovine myoblasts inhibited the 
formation of myotubes, and that this inhibition increased as 
the dose of myostatin increased.  Northern blots of the 
culture medium detected decreased expression of MyoD and 
myogenin, important determining factors in myogenesis.  
Rios, Carneiro, Arce, and Devesa (2002) came to the same 
conclusion by examining the overexpression of endogenous 
myostatin. 
Myostatin seems to have some other peripheral 
effects.  It negatively regulates apoptosis in muscle cells 
(Rios et al. 2001), while expression of myostatin antisense 
RNA has the opposite effect.  This is an important result 
because it shows that while myostatin overexpression does 
not lead to excess muscle production, it does not achieve 
this by causing the death of muscle cells.  This data, along 
with those showing that myostatin inhibits myoblast 
proliferation and differentiation, demonstrates how at the 
biochemical level myostatin mutations can lead to the 
observed double muscled phenotypes. 
 
Physiological Influences of Myostatin 
 
Myostatin is well characterized in terms of its physiological 
effects on muscle mass through both hyperplasia and 
hypertrophy.  Muscle hyperplasia refers to an increase in the 
number of muscle fibers present while muscle hypertrophy 
refers to an increase in the volume of muscle fibers already 
present.  Hyperplasia is usually regulated at the level of 
myoblast differentiation and proliferation while hypertrophy is 
regulated in mature skeletal muscle fibers. 
The original study by McPherron et al. (1997) 
produced a lot of information regarding gross anatomical 
changes in homozygous myostatin knockout mice.  These 
mice were almost 30% larger than controls and the mass 
was distributed throughout the body in increased skeletal 
muscle.  The amount of weight increase in individual 
muscles correlated well with levels of myostatin expression 
in those muscles.  Histological analysis revealed that the 
increase in muscle mass was due to both hyperplasia and 
hypertrophy, with the number of fibers increased by 86% and 
fiber size increased by 49%.  Every study done since this 
original has documented similar increases in muscle size, 
such as that done by Mosher et al. (2007) examining 
whippets heterozygous for a myostatin mutation.  Amthor, 
Otto, Macharia, McKinnell, and Patel (2006) noted increased 
muscle mass as well as some histological changes in 
muscle fiber composition in a myostatin deficient mouse line.  
Zebrafish also have a myostatin gene that results in 
increased muscle mass when knocked out (Xu, Wu, Zohar, 
and Du, 2003).  Although the original studies in mice 
suggested an increase in muscle mass through both 
hyperplasia and hypertrophy, Yang et al. (2001) noted only 
an increase in hypertrophy with no significant hyperplasia.  
McCroskery, Thomas, Maxwell, Sharma, and Kambadur 
(2003) showed that myostatin decreased muscle stem cell 
activation, consistent with the hypothesis that myostatin 
deficiency leads to hyperplasia.  A novel drug-inducible 
knockout was used to study the effects of post-
developmental myostatin knockout by Welle, Bhatt, Pinkert, 
Tawil, and Thornton (2006).  They engineered transgenic 
mice with a drug-inducible gene that expresses Cre 
recombinase and a form of the myostatin gene with loxP 
sites flanking one of the exons.  After the mice reached 
adulthood, they were given the drug, which knocked out the 
myostatin gene.  The result was mice with 25% greater 
muscle mass after 3 months of near-complete myostatin 
suppression.  The researchers measured fiber size and 
claimed that the increase in fiber size (hypertrophy alone) 
was enough to account for the gains in overall mass.  This is 
somewhat unsatisfying; a complete analysis would have 
included a fiber count to rule out hyperplasia.  Nevertheless, 
at this point it seems that myostatin knockout during 
development leads to hyperplasia and hypertrophy, while 
post-developmental knockout leads primarily to hypertrophy. 
Interestingly, myostatin also has a significant 
effect on adipose tissue.  Artaza et al. (2005) used a marker 
of adipogenesis with pluripotent cells and either endogenous 
myostatin or myostatin antibodies to demonstrate that 
myostatin promotes adipogenesis and myostatin antibodies 
suppress adipogenesis.  Lin et al. (2002) showed that after 
12 weeks myostatin deficiency led to decreased fat pad 
mass, and this age-dependent fat mass decrease has been 
echoed in other studies such as those done by McPherron 
and Lee (2002).  Feldman, Streeper, Farese, and Yamamoto 
(2006) demonstrated that myostatin can determine the fate 
of multipotent stem cells, but not preadipocytes, and that this 
effect leads to adipocytes with increased insulin sensitivity.  
Molecularly then, myostatin has favorable effects on the 
development of both skeletal muscle and adipose tissue. 
 
Myostatin-based Therapeutics 
 
Myostatin seems to be the ideal candidate for a therapeutic 
target in diseases that involve muscle wasting.  When 
Gonzalez-Cadavid et al. (1998) mapped the myostatin gene 
they also correlated serum myostatin concentrations with 
muscle wasting in HIV-infected males.  The more muscle 
wasting was observed, the higher the myostatin 
concentration.  The side effects of myostatin mutations, if not 
nonexistent, are undocumented in many animal studies, and 
the known natural mutations in humans thus far have not 
demonstrated any pathological risks.  A common concern is 
that myostatin may influence heart muscle, but Artaza et al. 
(2007) found that even though myostatin expression is 
related to left ventricular mass in mice, heart performance is 
not impacted as measured by the ejection fraction. 
Some studies have suggested that myostatin 
treatments may be effective in ameliorating diseases.  It has 
been found that patients with muscular atrophy have 
increased levels of myostatin (Wojcik, Nogalska, Engel, & 
Askanas, 2008).  Independently, Gilson et al. (2007) showed 
that myostatin completely alleviated atrophy associated with 
glucocorticoid use.  Bogdanovich et al. (2002) observed both 
increases in muscular size and functional improvements in 
the mdx mouse model of Duchenne Muscular Dystrophy 
(DMD) using a myostatin antibody.  The same group later 
found that using the myostatin propeptide fused to an 
antibody was a more effective strategy for increasing 
functional markers of the disease progression in the mdx 
mouse (Bogdanovich, Perkins, Krag, Whittemore, & 
Khurana, 2005).  In another situation, Zhao, Wall, and Yang 
(2005) also used propeptide-mediated inhibition of myostatin 
to prevent a high-fat diet from inducing insulin resistance and 
obesity in mice, suggesting that myostatin-based treatments 
may be effective in treating diabetes and other metabolic 
disorders characterized by insulin resistance. 
Myostatin inhibition does not seem to affect 
physiological parameters besides muscle mass in mice 
(Whittemore et al. 2003).  Furthermore, there are many 
diseases in which muscle wasting or lack of muscular 
development is either the cause or side effect of the disease, 
so the potential to help patients seems enormous.  With this 
in mind, recent myostatin research has focused on 
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developing effective inhibition strategies.  The most common 
methods for knocking out myostatin have been either 
genetically engineered animals with myostatin mutations, 
animals expressing a myostatin antisense RNA, or anti-
myostatin antibodies.  In fact, a phase I/II clinical trial with a 
myostatin-targeting antibody administered to muscular 
dystrophy patients was recently completed and although not 
yet published, preliminary reports verify the safety of the 
drug (Wagner et al. 2008).   
In my opinion, exploiting RNA interference (RNAi) 
should be the future goal of myostatin therapeutics, although 
this approach has only been used in a few myostatin-related 
studies to date.  Acosta, Carpio, Borroto, Gonzalez, and 
Estrada (2005) used double stranded RNA (dsRNA) to 
suppress myostatin in zebrafish, leading to the double 
muscled phenotype for that species.  Magee et al (2006) 
published the most impressive report of small interfering 
RNA (siRNA) being able to suppress myostatin mRNA by 
27% leading to a 10% increase in skeletal muscle mass.  
This is modest compared to other forms of knockout, thus 
more research needs to be done.  Because the RNAi system 
offers the possibility of tightly controlled and efficient 
silencing as demonstrated in other studies, this system 
should be explored as a method of myostatin silencing 
(Novina & Sharp, 2004). 
 
Social and Ethical Considerations with Myostatin-
blocking Treatments 
 
Clearly treatments that target myostatin have the potential to 
alleviate the suffering of many patients with a plurality of 
diseases.  This type of therapy, however, may also attract 
the interest of people on the other end of the health 
spectrum: athletes.  A recent study by Amthor et al. (2007) 
shows that myostatin deficient mice display impaired force 
production.  This study stands in contrast to the findings by 
Mosher et al. (2007) mentioned earlier, that states that 
heterozygote whippets not only show increased muscle 
mass but also enhanced racing performance.  Clearly racing 
performance is dependent on the ability to produce force 
rapidly.  The difference may be that the first study examined 
animals homozygous for myostatin mutations and the 
second examined heterozygotes, or it may be that there is 
an interspecies difference.  The fact that lack of myostatin to 
some degree can enhance performance might make 
myostatin-based therapeutics an attractive option for elite 
athletes looking to gain an edge in competition.  
Traditionally, athletes have turned to other performance 
enhancing drugs like steroids and growth hormone for 
strength sports, or EPO for endurance sports.  Myostatin 
treatment, because it may prove to have significantly less 
side effects than other performance enhancers, will certainly 
be considered by some a viable and safer method.  Even if 
there are side effects, athletes have proven their willingness 
to gamble with their health for the sake of greater 
performance.   
This leads directly into a discussion of what we as 
a society consider athleticism.  We watch sporting events 
and are thrilled to see world records continuously being 
broken, but we shun professional athletes who achieve 
these heights by what we consider cheating.  Surely taking 
myostatin inhibitors would be cheating just as much as 
taking steroids is.  But what about boys such as the one 
described above that have a natural myostatin mutation?  
Surely he should not be barred from Olympic competitions, 
but then why should we persecute people who simply try to 
level the playing field with genetic wonders like this by taking 
performance enhancers?  These are issues that are 
important to society and also to me.  Having been a 
competitive athlete for much of my life, I find discussions like 
this compelling.  With the first myostatin inhibitors having 
already completed phase II clinical trials, the day when we 
have to deal with this issue is upon us.  It is no surprise that 
here, like in other cases, biomedical technology has 
advanced far beyond what biomedical ethics has 
considered. 
 
Note: Eukaryon is published by students at Lake Forest 
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